{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:40:12Z","timestamp":1784043612019,"version":"3.55.0"},"reference-count":28,"publisher":"Georg Thieme Verlag KG","issue":"04","license":[{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Neuropsiquiatr"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background\u2003Meige's syndrome is a type of facial dystonia characterized by the simultaneous occurrence of blepharospasm and oromandibular dystonia. Although botulinum toxin type A (OBTA) injections are the standard treatment, evidence of their effectiveness and safety in this scenario is still lacking.<\/jats:p><jats:p>\n          Objective\u2003Our research aimed to evaluate the improvement and occurrence of side effects following injections of onabotulinum toxin type A (OBTA) in patients with Meige's syndrome.<\/jats:p><jats:p>\n          Methods\u2003Patients with Meige's syndrome undergoing botulinum toxin injections were enrolled in this study. We assessed dystonia intensity before and 14 days after OBTA injection using the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) to measure the response of symptoms in the eyes (blepharospasm) and mouth (oromandibular dystonia). Other variables, such as dosage, side effects, and demographic data, were also recorded.<\/jats:p><jats:p>\n          Results\u2003The study included 41 participants, with a mean age of 67.7 years and a female-to-male ratio of 3.5:1. The mean BFMDRS score before the injections was 8.89, and after 14 days, it was 2.88. The most reported side effect was ptosis, with a 7.3% incidence. OBTA significantly reduced dystonia severity (p\u2009&lt;\u20090.0001). The clinical response for the blepharospasm component was superior to the oromandibular dystonia component.<\/jats:p><jats:p>\n          Conclusion\u2003Our results support that OBTA seems to be an effective and safe therapeutic option for treating Meige's syndrome. The effect of OBTA was more pronounced in the treatment of blepharospasm than in oromandibular dystonia.<\/jats:p>","DOI":"10.1055\/s-0044-1785691","type":"journal-article","created":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T00:09:22Z","timestamp":1713571762000},"page":"001-007","source":"Crossref","is-referenced-by-count":3,"title":["Effects of onabotulinum toxin type A injections in patients with Meige's syndrome"],"prefix":"10.1055","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3985-2529","authenticated-orcid":false,"given":"Alexia","family":"Duarte","sequence":"additional","affiliation":[{"name":"Universidade Federal do Paran\u00e1, Setor de Ci\u00eancias da Sa\u00fade, Curitiba PR, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4921-2939","authenticated-orcid":false,"given":"L\u00e9o","family":"Coutinho","sequence":"additional","affiliation":[{"name":"Universidade Federal do Paran\u00e1, Programa de P\u00f3s-Gradua\u00e7\u00e3o em Medicina Interna, Curitiba PR, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9494-9759","authenticated-orcid":false,"given":"Francisco Manoel Branco","family":"Germiniani","sequence":"additional","affiliation":[{"name":"Universidade Federal do Paran\u00e1, Hospital de Cl\u00ednicas, Departamento de Cl\u00ednica M\u00e9dica, Setor de Neurologia, Curitiba PR, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2305-1073","authenticated-orcid":false,"given":"H\u00e9lio Afonso Ghizoni","family":"Teive","sequence":"additional","affiliation":[{"name":"Universidade Federal do Paran\u00e1, Setor de Ci\u00eancias da Sa\u00fade, Curitiba PR, Brazil."},{"name":"Universidade Federal do Paran\u00e1, Hospital de Cl\u00ednicas, Departamento de Cl\u00ednica M\u00e9dica, Setor de Neurologia, Curitiba PR, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,4,19]]},"reference":[{"issue":"07","key":"ref1","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/mds.25475","article-title":"Phenomenology and classification of dystonia: a consensus update","volume":"28","author":"A Albanese","year":"2013","journal-title":"Mov Disord"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jns.2016.11.053","article-title":"Meige's syndrome: History, epidemiology, clinical features, pathogenesis and treatment","volume":"372","author":"S Pandey","year":"2017","journal-title":"J Neurol Sci"},{"issue":"07","key":"ref3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.parkreldis.2009.04.006","article-title":"Meige syndrome: what's in a name?","volume":"15","author":"M S LeDoux","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"630221","DOI":"10.3389\/fneur.2021.630221","article-title":"Blepharospasm, Oromandibular Dystonia, and Meige Syndrome: Clinical and Genetic Update","volume":"12","author":"H Ma","year":"2021","journal-title":"Front Neurol"},{"issue":"01","key":"ref5","doi-asserted-by":"publisher","first-page":"15753","DOI":"10.1038\/s41598-021-95333-8","article-title":"Regional metabolic and network changes in Meige syndrome","volume":"11","author":"J Liu","year":"2021","journal-title":"Sci Rep"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"103013","DOI":"10.1016\/j.nicl.2022.103013","article-title":"Thalamic structural connectivity profiles in blepharospam\/Meige's syndrome","volume":"34","author":"T Mantel","year":"2022","journal-title":"Neuroimage Clin"},{"issue":"01","key":"ref7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ncl.2014.09.002","article-title":"Diagnosis and treatment of dystonia","volume":"33","author":"H A Jinnah","year":"2015","journal-title":"Neurol Clin"},{"issue":"05","key":"ref8","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1468-1331.2006.01537.x","article-title":"A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS\/MDS-ES Task Force","volume":"13","author":"A Albanese","year":"2006","journal-title":"Eur J Neurol"},{"issue":"12","key":"ref9","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1136\/jnnp-2020-323701","article-title":"Pallidal deep brain stimulation in primary Meige syndrome: clinical outcomes and psychiatric features","volume":"91","author":"Q Hao","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"08","key":"ref10","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/mds.27072","article-title":"Botulinum toxin: State of the art","volume":"32","author":"J Jankovic","year":"2017","journal-title":"Mov Disord"},{"issue":"04","key":"ref11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3390\/toxins12040269","article-title":"Treatment of Blepharospasm and Oromandibular Dystonia with Botulinum Toxins","volume":"12","author":"T JW Hassell","year":"2020","journal-title":"Toxins (Basel)"},{"issue":"01","key":"ref12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1212\/wnl.35.1.73","article-title":"Validity and reliability of a rating scale for the primary torsion dystonias","volume":"35","author":"R E Burke","year":"1985","journal-title":"Neurology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.4103\/0028-3886.226439","article-title":"Dystonia: A review","volume":"66","author":"A Batla","year":"2018","journal-title":"Neurol India"},{"issue":"03","key":"ref16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/archneur.1981.00510030041005","article-title":"Clinical features of Meige's disease (idiopathic orofacial dystonia): a report of 17 cases","volume":"38","author":"E S Tolosa","year":"1981","journal-title":"Arch Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000475701","article-title":"Brueghel Syndrome or Meige Syndrome? Two Sides of a Same Disease","volume":"41","author":"M B\u00e9reau","year":"2018","journal-title":"Front Neurol Neurosci"},{"issue":"04","key":"ref18","first-page":"371","article-title":"Blepharospasm: demographic and clinical survey of 250 patients","volume":"16","author":"J Jankovic","year":"1984","journal-title":"Ann Ophthalmol"},{"issue":"01","key":"ref19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.4103\/0028-3886.222872","article-title":"Botulinum toxin in Meige's syndrome: A video-based case series","volume":"66","author":"S Pandey","year":"2018","journal-title":"Neurol India"},{"issue":"12","key":"ref20","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1136\/bjo.80.12.1073","article-title":"Treatment selections of 239 patients with blepharospasm and Meige syndrome over 11 years","volume":"80","author":"J A Mauriello Jr","year":"1996","journal-title":"Br J Ophthalmol"},{"issue":"01","key":"ref21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ajo.2013.02.001","article-title":"Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome","volume":"156","author":"C N Czyz","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"01","key":"ref22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00415-019-09581-w","article-title":"Treatment of blepharospasm and Meige's syndrome with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice","volume":"267","author":"A Jochim","year":"2020","journal-title":"J Neurol"},{"issue":"09","key":"ref23","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1212\/wnl.53.9.2102","article-title":"Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up","volume":"53","author":"E K Tan","year":"1999","journal-title":"Neurology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.toxicon.2017.09.003","article-title":"An update on new and unique uses of botulinum toxin in movement disorders","volume":"147","author":"J Jankovic","year":"2018","journal-title":"Toxicon"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.4103\/0028-3886.226441","article-title":"Botulinum toxin in movement disorders","volume":"66","author":"P Tater","year":"2018","journal-title":"Neurol India"},{"issue":"08","key":"ref26","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1586\/14737175.2014.936387","article-title":"Ultrasound-guided botulinum toxin injections in neurology: technique, indications and future perspectives","volume":"14","author":"U Walter","year":"2014","journal-title":"Expert Rev Neurother"},{"issue":"05","key":"ref27","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.tripleo.2003.08.011","article-title":"Treatment of perioral dystonia with botulinum toxin in 4 cases of Meige's syndrome","volume":"96","author":"E M\u00f8ller","year":"2003","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.parkreldis.2018.05.014","article-title":"Post-operative electrode location and clinical efficacy of subthalamic nucleus deep brain stimulation in Meige syndrome","volume":"58","author":"C Yao","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"issue":"02","key":"ref29","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/ner.13304","article-title":"Similar Long-Term Clinical Outcomes of Deep Brain Stimulation With Different Electrode Targets for Primary Meige Syndrome: One Institution's Experience of 17 Cases","volume":"24","author":"H Tian","year":"2021","journal-title":"Neuromodulation"},{"issue":"07","key":"ref30","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1002\/mds.25579","article-title":"Dystonia rating scales: critique and recommendations","volume":"28","author":"A Albanese","year":"2013","journal-title":"Mov Disord"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1785691.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T14:01:06Z","timestamp":1730815266000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1785691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":28,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2024,4,5]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["s00441785691"],"URL":"https:\/\/doi.org\/10.1055\/s-0044-1785691","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0004-282X","1678-4227"],"issn-type":[{"value":"0004-282X","type":"print"},{"value":"1678-4227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]}}}